Navigating the Molecular Landscape: ASCO Publishes Comprehensive Series on ctDNA and Personalized Oncology

Alexandria, Va. - The American Society of Clinical Oncology (ASCO) today announced the publication of a special series of articles in JCO Oncology Practice (JCO OP) focused on molecular testing and circulating tumor DNA (ctDNA) in oncology practice. This comprehensive series provides clinicians with practical guidance on using molecular information to personalize cancer care.

Molecular testing, including the analysis of ctDNA shed from tumors into the bloodstream, is transforming how we diagnose, treat, and monitor cancer. By analyzing the genetic makeup of tumors or ctDNA, clinicians gain valuable insights to guide treatment decisions. However, keeping pace with rapid advances in this field can be challenging.

This special series in JCO OP addresses this need with articles written by experts. The series covers a wide range of topics, including clinical applications in various cancer types, administrative and ethical considerations, and addressing disparities in access.

"This special series not only provides a comprehensive overview of the current state of molecular testing, but also offers practical guidance on how to integrate these advances into everyday practice to improve patient outcomes," said John Burke, MD, one of the series editors. "We believe this will be an essential resource for oncologists seeking to provide the most informed and personalized care for their patients."

Article Highlights

• "Clinical applications of circulating tumor DNA profiling in gastrointestinal cancers," exploring how ctDNA analysis can lead to less invasive diagnostic procedures and more precise treatment selection.
• "Ethical and clinical considerations in ordering and responding to molecular diagnostics and ctDNA as the science evolves," offering guidance on navigating complex ethical dilemmas in this rapidly changing field.

The full series is available on the JCO OP website.

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer's full continuum. Learn more at www.ASCO.org, and follow us on Facebook, X, LinkedIn, Instagram, and YouTube.

About JCO Journals:

ASCO's Journals-including the Society's flagship publication, Journal of Clinical Oncology-serve readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research that informs the delivery of high-quality patient care across the globe. Explore the research and learn more about becoming a JCO author at www.ascopubs.org.